Ophthalmologic Irrigation Solutions and Method

Patent metadata

Field	Value
Publication number	US-2017312295-A1
Application number	US-201715414930-A
Country	US
Kind code	A1
Filing date	Jan 25, 2017
Priority date	Jul 30, 2002
Publication date	Nov 2, 2017
Grant date	—

Abstract

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1 . A composition for use in promoting mydriasis during an intraocular ophthalmologic procedure, comprising a local anesthetic agent combined with a mydriatic agent that is an alpha-1 adrenergic receptor agonist in a physiologic carrier solution, wherein the alpha-1 adrenergic receptor agonist is included in the solution at a concentration of no more than 1,000,000 nanomolar and the local anesthetic agent is included in the solution at a concentration of no more than 100,000,000 nanomolar and wherein the agents are included in therapeutically effective amounts for mydriasis during the procedure when delivered intraocularly.

2 . The composition of claim 1 , wherein the local anesthetic agent is selected from the group consisting of lidocaine, tetracaine, bupivacaine, and proparacaine.

3 . The composition of claim 1 , wherein the alpha-1 adrenergic receptor agonist is selected from the group consisting of phenylephrine, epinephrine and oxymetazoline.

4 . The composition of claim 1 , wherein the alpha-1 adrenergic receptor agonist is selected from the group consisting of phenylephrine and epinephrine.

5 . The composition of claim 4 , wherein the local anesthetic agent is selected from the group consisting of lidocaine, tetracaine, bupivacaine, and proparacaine.

6 . The composition of claim 1 , wherein the physiologic carrier solution comprises a liquid irrigation carrier.

7 . The composition of claim 6 , wherein the liquid irrigation carrier comprises a balanced salt solution.

8 . The composition of claim 1 , wherein the solution further comprises a non-steroidal anti-inflammatory drug (NSAID).

9 . The composition of claim 8 , wherein the NSAID is selected from the group consisting of flurbiprofen, suprofen, diclofenac, ketoprofen and ketorolac.

10 . The composition of claim 1 , wherein the alpha-1 adrenergic receptor agonist is included in the solution at a concentration of no more than 500,000 nanomolar and the local anesthetic agent is included in the solution at a concentration of no more than 1,200,000 nanomolar.

11 . A composition for use in promoting mydriasis during an intraocular ophthalmologic procedure, comprising a local anesthetic agent combined with a mydriatic agent that is an alpha-1 adrenergic receptor agonist in a physiologic carrier solution, wherein the local anesthetic agent and the alpha-1 adrenergic receptor agonist are included in therapeutically effective amounts to promote mydriasis during the procedure when delivered intraocularly and at concentrations less than that used for conventional topical or systemic delivery.

12 . The composition of claim 11 , wherein the alpha-1 adrenergic receptor agonist is included in the solution at a concentration of no more than 500,000 nanomolar and the local anesthetic agent is included in the solution at a concentration of no more than 1,200,000 nanomolar.

Assignees

• Omeros Corp

Inventors

• Demopulos Gregory A
• Palmer Pamela Pierce
• Herz Jeffrey M

Classifications

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/02

  without antiinflammatory effect · CPC title

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title